1. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M (1999) In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59: 5012–5016
2. Beauregard DA, Pedley RB, Hill SA, Brindle KM (2002) Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15: 99–105
3. Blakey DC, Douglas S, Revill M, Ashton SA (1999) The novel vascular targeting agent ZD6126 causes rapid morphology changes leading to endothelial cell detachment at non-cytotoxic concentrations. Clin Exp Metastasis 17: 776
4. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Anti-tumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974–1983
5. Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80 (Suppl 1): 57–64